Genmab — December 2023
-
I find it comforting that BioNTech is willing to try the second Hexabody. After all, the technology has not yet been proven. But it would not surprise me if they have also seen the data on Hexabody-DR5/DR5 . Doubt they are allowed to see Hexabody-CD38 data early though.
-
-
-
Johnson & Johnson’s prescription for growthhttps://www.proinvestor.com/investornyt/1087102/johnson-amp-johnsonrsquos-prescription-for-growth
-
"Key pharmaceuticals like Darzalex, Carvykti, and Stelara are pivotal revenue drivers, illustrating J&J's steadfast commitment to developing and delivering life-altering treatments. These flagship drugs continue to showcase robust market demand, underpinning the company's revenue expectations"
.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind